qsc tirzepatide Lilly's Q1 revenue surge overshadowed by CVS dumping Zepbound for Wegovy qsc tirzepatide Tirzepatide 50mg |

Individual timelines vary based on starting dose, metabolism, and adherence to nutrition and exercise recommendations

What the Clinical Evidence Shows While large-scale randomized controlled trials specifically measuring testosterone as a primary endpoint in tirzepatide users are still emerging, the available evidence is encouraging: The SURMOUNT trials demonstrated average weight losses of 15-22.5% of body weight, a degree of fat reduction strongly associated with testosterone recovery in men with obesity-related hypogonadism (Jastreboff et al., 2022, NEJM )

Eli Lilly developed it, and a Phase 2 trial published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity and reported a mean body-weight reduction of 24.2% at 48 weeks on the 12mg once-weekly dose

Autologous (Self-donation): eligible 3 months after surgery